A Liposomal Irinotecan and S-1 Combination is Shown to be Efficacious in the Treatment of Metastatic Pancreatic Acinar Cell Carcinoma: A Case Report

Abstract

Pancreatic acinar cell carcinoma (PACC) represents a rare malignancy within the pancreatic tumor spectrum. Owing to its rarity, the establishment of a standardized chemotherapy regimen for patients presenting with either metastatic disease or recurrence after radical surgery remains elusive. Most previous studies and case reports have used gemcitabine-based and 5-fluorouracil-based regimens, however, no previous study has reported the use of liposomal irinotecan in combination with S-1. In this report, we present a patient with PACC who experienced disease progression with liver metastasis after radical tumor resection followed by chemoradiotherapy. The patient underwent second-line treatment with liposomal irinotecan in conjunction with S-1. Encouragingly, the patient has remained free of recurrence and progression during a follow-up period of 2 years and 3 months.

Keywords

• liposomal irinotecan
• pancreatic acinar cell carcinoma
• s-1